



## OPEN Versatile magnetic configuration for the control and manipulation of superparamagnetic nanoparticles

Alessandro Surpi<sup>1,6</sup>✉, Tatiana Shelyakova<sup>2,6</sup>✉, Mauro Murgia<sup>1,3</sup>, José Rivas<sup>4</sup>, Yolanda Piñero<sup>4</sup>, Pierpaolo Greco<sup>3,5</sup>, Milena Fini<sup>2</sup> & Valentin Alek Dediu<sup>1</sup>✉

The control and manipulation of superparamagnetic nanoparticles (SP-MNP) is a significant challenge and has become increasingly important in various fields, especially in biomedical research. Yet, most of applications rely on relatively large nanoparticles, 50 nm or higher, mainly due to the fact that the magnetic control of smaller MNPs is often hampered by the thermally induced Brownian motion. Here we present a magnetic device able to manipulate remotely in microfluidic environment SP-MNPs smaller than 10 nm. The device is based on a specifically tailored configuration of movable permanent magnets. The experiments performed in 500  $\mu\text{m}$  capillary have shown the ability to concentrate the SP-MNPs into regions characterized by different shapes and sizes ranging from 100 to 200  $\mu\text{m}$ . The results are explained by straightforward calculations and comparison between magnetic and thermal energies. We provide then a comprehensive description of the magnetic field intensity and its spatial distribution for the confinement and motion of magnetic nanoparticles for a wide range of sizes. We believe this description could be used to establish accurate and quantitative magnetic protocols not only for biomedical applications, but also for environment, food, security, and other areas.

Magnetic nanoparticles (MNP) have found multiple uses across a wide spectrum of biomedical applications<sup>1,2</sup> such as hyperthermia for cancer treatment<sup>3</sup>, remotely controlled drug delivery<sup>4</sup> and others both in-vivo<sup>5,6</sup> and in-vitro<sup>7–9</sup> environments. In tissue engineering, the magnetic manipulation of cells is used in regenerative medicine<sup>10</sup> for efficient cell loading inside scaffolds for bone tissues regeneration<sup>11</sup> or to induce differentiation of MNP-laden embryonic stem cells<sup>12</sup>. Finally, MNP-mediated magnetic reprogramming of cellular function—magnetogenetics—is an emerging field in cell biology<sup>13</sup> and neuroscience<sup>14</sup>.

MNP-based technologies enable the concentration and the manipulation of various bio-agents (BioA) both in-vivo and in-vitro. This is done by capturing the BioAs on selectively functionalized nanoparticle surfaces and then by guiding remotely the formed conjugates by external magnetic field. The superparamagnetic nanoparticles (SP-MNP) represent the most preferable choice for this kind of applications, due to their low aggregation probability and high magnetisation activated by external magnetic field.

Magnetic concentration, manipulation, and separation of BioAs is critically important for biosensing, and other in-vitro applications. The magnetic removal of BioAs from analysed solutions is highly selective, efficient, and often faster than centrifugation or filtration<sup>15</sup>. It enables efficient manipulations across microfluidics and enhances the sensors performance by removing the interfering species, increasing the concentration of BioA by orders of magnitude. The magnetic technologies are thus increasingly employed to concentrate and detect cells<sup>16,17</sup> and molecular biomarkers<sup>18,19</sup>. Also, the realization of microfluidic devices based on the magnetic actuation of MNPs<sup>20</sup> is expected to circumvent some critical issues in microfluidics, where the mixing and processing of fluids at the nanoscale become increasingly inefficient because of the dominance of capillary and viscous forces<sup>21</sup>.

<sup>1</sup>Istituto per lo Studio dei Materiali Nanostrutturati (CNR-ISMN), 40129 Bologna, Italy. <sup>2</sup>IRCCS Istituto Ortopedico Rizzoli, SC Scienze e Tecnologie Chirurgiche, 40136 Bologna, Italy. <sup>3</sup>Italian Institute of Technology, Center for Translational Neurophysiology (IIT), 44121 Ferrara, Italy. <sup>4</sup>Laboratorio de Nanomagnetismo y Nanotecnologia, Departamento de Fisica Aplicada, Instituto NANOMAG, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain. <sup>5</sup>Dipartimento di Neuroscienze e Riabilitazione, Università di Ferrara, 44121 Ferrara, Italy. <sup>6</sup>These authors contributed equally: Alessandro Surpi and Tatiana Shelyakova. ✉email: alessandro.surpi@ismn.cnr.it; tatiana.shelyakova@ior.it; valentin.dediu@cnr.it

The development of technologies for magnetic concentration and manipulation has progressed along different lines and approaches, depending on the specific problems which need to be addressed. It must be mentioned that the manipulation of superparamagnetic species on short scales, necessary for many biomedical applications, requires reasonably strong fields to align the SP-MNP magnetic moments, but also sharp magnetic gradients to provide strongly localized confinement of nanoparticles.

The application of electromagnets, both copper-based and superconducting, allows to achieve very high magnetic fields ( $> 1$  T)<sup>22</sup> but they are characterised by smooth spatial distribution, basically homogeneous on typical biological scales<sup>23</sup>. Permanent magnets, especially those having rectangular or needle-like shapes<sup>19,24–26</sup>, may generate relatively high fields (typically in sub-Tesla range) together with sharp magnetic gradients on mm and sub-mm scales<sup>27,28</sup>. Also, their cost is orders of magnitude cheaper than electromagnets and their handling and positioning is by far easier. Furthermore, advanced micro-scale patterning technologies allow to achieve enormous magnetic gradients in the close vicinity of the fabricated micromagnets<sup>29–31</sup>. Also, natural micro- and nanofeatures in continuous non patterned ferromagnetic films, such as magnetic domain walls (DW) can be used to manipulate magnetic particles<sup>32</sup> and particle-protein conjugates<sup>33</sup> on the micro-scales. Indeed, the choice of the magnet size, shape and strength depends on the specific application.

While the research on magnetic concentration and related manipulation of SP-MNPs has been strongly promoted in the biomedical field, the applications are not limited to it but have proved to be technologically efficient and cost-effective also in other areas, such as waste remediation, large-scale water purification, environmental monitoring, food production, industrial separation of minerals for mining and of metals for nuclear industry (see ref<sup>15</sup> and reference therein).

In this paper we experimentally demonstrate the efficient confinement of small superparamagnetic nanoparticles with a  $\text{Fe}_3\text{O}_4$  magnetic core by specifically tailored permanent magnets. The experimental data are in good agreement with employed modelling based on finite element analysis. We also define the conditions for a reliable confinement of nanoparticles as function of their diameters and for the motion of concentrated MNPs across microfluidic channels.


**Synthesis and characterization of MNPs.** Single-core superparamagnetic iron oxide nanoparticles coated by polyacrylic acid ( $\text{Fe}_3\text{O}_4@PAA$ ) were employed to investigate the magnetic confinement. The  $\text{Fe}_3\text{O}_4@PAA$  nanoparticles were obtained by co-precipitation, following Massart's method<sup>34</sup>. The reaction was carried out for 1 h at 60 °C. The SP-MNP were characterized by different techniques to reveal their structural and magnetic quality. Transmission electron microscopy (TEM) micrographs were taken by JEOL JEM-1011 microscope operating at 100 kV and by LIBRA 200FE microscope for High-Resolution Transmission Electron Microscopy (HRTEM) operating at 200 kV. Direct current (DC) magnetization curves of the dried samples were measured using a vibrating sample magnetometer (VSM) (DMS, Lowell, MA, USA). TEM images (Fig. 1a) reveal an irregular spherical morphology with a medium magnetic core size distribution having a maximum at about 7 nm (Fig. 1b) and a total diameter of about 10 nm. HRTEM microscopy (Fig. 1c) discloses the crystalline nature of the iron oxide core with an inverse spinel structure, as proved by Selected-Area Electron Diffraction (SAED) analysis. A typical magnetization curve for the  $\text{Fe}_3\text{O}_4@PAA$  nanoparticles is shown in Fig. 1d. The curve has a standard superparamagnetic shape with vanishingly low magnetic hysteresis and negligible coercivity ( $H_C = 1.6$  Oe). The saturation magnetization of 63 emu/g<sub>Fe<sub>3</sub>O<sub>4</sub></sub> is comparable with the highest values reported in literature for iron oxide SP-MNP<sup>35</sup>.

**Confinement tool.** A magnetic device (MagD) has been designed and fabricated to confine the SP-MNPs. The device consists of a quartz capillary placed between two NdFeB permanent magnets (Fig. 2a). The magnets are fixed by a fork-like holder and can be moved by a linear actuator along the capillary at a speed up to 120  $\mu\text{m/s}$ . The capillary is loaded with MNP suspension by using a peristaltic pump connected by a silicon pipe. Direct observation of nanoparticle behaviour in quartz capillary under the effect of magnetic fields is performed by a microscope-connected CCD camera (Dino-Lite Pro, AnMo Electronics Corporation, Hsinchu City, Taiwan). Capillaries with diameters ranging from 500 to 3000  $\mu\text{m}$  were used for the experiments—where the smallest size simulates microfluidic channels—and medical-grade silicone tubes (Silastic® Rx 50 medical grade tubing) routinely used for intravenous therapies.


Considering the permanent magnets, our preference was given to rectangular shapes due to their expected sharp confinement geometry. To define their size and orientation, COMSOL simulations of cubic magnets with edges from 2 to 10 mm have been performed.

The  $5 \times 5 \times 5$  mm<sup>3</sup> magnets were found sufficiently strong to bring the MNPs magnetisation close to saturation values. Next, we focused on the magnets orientation with respect to the capillary. The edge-to-edge geometry (Fig. 2a,b) was established as the optimal configuration, providing a significantly narrower distribution than the face-to-face one (Fig. 2c). The simulation of the magnetic field distribution for two  $5 \times 5 \times 5$  mm<sup>3</sup> magnets distanced by 3 mm showed a clepsydra-like field distribution, with magnetic field reaching clear maxima (about 600 kA/m or about 7500 Oe) next to the magnets (red region). Yet, in the edge-to-edge case (Fig. 2b) the field is concentrated in a narrow sub-mm region with magnetic field of about 360 kA/m (about 4500 Oe) in the central point between the magnets, while in the face-to-face case (Fig. 2c) the generated field is broadly distributed with respective values of about 440 kA/m (about 5500 Oe). Even though both configurations generate magnetic fields able to bring the magnetisation of MNPs close to the saturation (see Fig. 1d), we have chosen the narrowest magnetic distribution to concentrate the nanoparticles in the smallest possible volume. The vertex-to-vertex configuration was also simulated and ruled out, because in spite of quite narrow field distribution it was characterized by lower magnetic field intensity.

The complete set of calculated parameters and a detailed explanation is presented below in the discussion part.



**Figure 1.** Fe<sub>3</sub>O<sub>4</sub>@PAA nanoparticle characterizations: (a) TEM image. (b) Statistical distribution of magnetic core diameters. (c) HRTEM image, where the red square denotes the area of highest crystalline quality. (d) Hysteresis loop at room temperature.



**Figure 2.** (a) Photo of the experimental MagD. (b) Calculated magnetic field distribution generated by the magnets in edge-to-edge configuration. For comparison in (c) we show magnetic field distribution simulated for magnets in face-to-face configuration. (b,c) Have a common colour scale for magnetic field values and the arrows show the directions of magnets magnetization.


### Experimental section: confinement and manipulation of MNP

To investigate the confinement of the employed nanoparticles in our magnetic tool, we injected a 50  $\mu\text{g}/\text{mL}$  concentrated suspension of MNP in the 500  $\mu\text{m}$  wide capillary placed precisely at the midpoint between magnets. The MNP suspension represents a small part of the circulating liquid consisting mainly of the de-ionized water (18  $\text{M}\Omega\text{-cm}$ ) and is kept separated from it by two air gaps (at about 5 cm from each other) to avoid mixing and subsequent dilution. As can be seen in Fig. 3a, the nanoparticles get concentrated (in ca. 10 min) into a stable configuration resembling the magnetic field distribution simulated by COMSOL (Fig. 2b). It consists of two lobes at the capillary wall next to the magnets connected by a narrow “bridge”: essentially, a clepsydra-shaped configuration (CSC) (Fig. 3a). This shape results from a joint effect of the magnetic field and the spatial constraints produced by the capillary.


This configuration appears very sensitive to any displacement of the capillary from the central symmetrical position between the magnets: shifting the capillary to either left or right, a blob-like droplet of MNPs forms at the capillary wall next to the closest magnet. This transition depends on the capillary size and on the distance between the magnets. For example, for a 500  $\mu\text{m}$  wide capillary and magnet separation of 3 mm even a 100  $\mu\text{m}$  displacement of the capillary to the left (Fig. 3b) is sufficient to break the CSC, while for magnet distancing of about 8 mm the clepsydra is stable even for displacements up to 200  $\mu\text{m}$ . Indeed, moving the capillary along the line connecting the magnets, the MNPs can sense regions where the magnetic energy is significantly higher than at the midpoint and are attracted there. Accordingly, maintaining the same concentration of nanoparticle and the 3 mm gap between the magnets, the employment of a capillary as wide as the separation distance leads the MNPs to concentrate in two dense blobs near the edges of magnets (Fig. 3c).

The CSC can remain stable even when magnets are moved along the capillary. It solidly follows the magnets along the capillary for a range of magnets speeds and separations. Figure 4 shows the example of such motion for the prototypical configuration, 500  $\mu\text{m}$  capillary and 3 mm magnet separation, at 60  $\mu\text{m}/\text{s}$  speed. We have further investigated the effect for magnets speed 30, 60, 120  $\mu\text{m}/\text{sec}$  and separation between magnets of 3, 5, 6, 8, and 10 mm to define the “stability window” for the motion of confined MNPs.


This stability window is represented by the green area in Fig. 5. Clearly, a strong correlation exists between the magnets separation and the highest speed at which the confined MNPs can solidly follow the magnets: the higher magnets separation the lower speed necessary to break the confinement. For magnets distanced by 10 mm the MNPs can be rigidly moved only at 20  $\mu\text{m}/\text{s}$ , while for separation smaller than 5 mm, the MNPs shape can be maintained even at the highest available speed: 120  $\mu\text{m}/\text{s}$ . All the experiments were done using the



**Figure 3.** Experimental realization of MNP confinement by permanent magnets separated by 3 mm. (a) A 500  $\mu\text{m}$  wide capillary is placed at the mid-point between magnets: MNPs are concentrated between the magnets in a clepsydra-shaped region spanning across the entire capillary section. (b) The 500  $\mu\text{m}$  wide capillary is displaced by 100  $\mu\text{m}$  from the midpoint to the left: MNPs coalesce into a blob-like configuration next to the nearest magnet. (c) For a 3 mm wide capillary (occupying the entire gap between magnets), the MNPs coalesce into dense blobs next to the magnets.



**Figure 4.** Dynamic behaviour of CSC. It solidly follows the magnets movement along the capillary while keeping its shape. Magnets speed: 60  $\mu\text{m}/\text{s}$ ; gap 3 mm; capillary 500  $\mu\text{m}$  wide. For sake of clarity, a dashed line has been superimposed as a reference. Time is given in mm:ss format and 00:00 corresponds to initial magnets position after CSC formation.



**Figure 5.** Stability window for the CSC upon translation in the 500  $\mu\text{m}$  capillary. Crosses mark the experimental data while green and red regions delimitate the parameter spaces where a CSC solidly follows the magnets or not, respectively. The data points corresponding to 5 mm to 120  $\mu\text{m/s}$ , 6 mm to 60  $\mu\text{m/s}$ , 10 mm to 30  $\mu\text{m/s}$  gave not reproducible experimental results in terms of stability and were excluded from the green/red regions.

MNP concentration of 50  $\mu\text{g/mL}$ . At one selected data point, namely at 3 mm and 30  $\mu\text{m/s}$ , lower concentrations of 10  $\mu\text{g/mL}$  and 3  $\mu\text{g/mL}$  have been also investigated, revealing no dependence of the CSC stability on the concentration.

### Modelling and discussion

To decrease the size of the magnetic particles from micro- to nanometres would be highly beneficial and would enable innovative high-throughput purification/separation methodologies. Yet, the broad use of nano-sized particles has been so far hindered because it is increasingly difficult to control by magnetic fields small sub-100 nm nanoparticles against the randomizing effects of thermal fluctuations. This has put significant limitations to magnetic manipulation. Large nanoparticles typically have magnetic remanence and thus a strong tendencies towards aggregation, whilst the control would be markedly facilitated in the superparamagnetic regime, induced by a size-dependent transition below a material-dependent critical diameter (about 20–25 nm for  $\text{Fe}_3\text{O}_4$ ) and characterized by no remanent magnetization at zero field<sup>36–38</sup>. Also, from a biotechnological point of view, the use of MNPs with sizes comparable to biological entities (for example, proteins (5–50 nm) or viruses (> 20 nm)) is highly advantageous.

To analyse and describe the experimental confinement data we must compare the magnetic and thermal energies acquired by SP-MNPs in our experimental conditions. Assuming the situation of thermal equilibrium, a magnetic particle is captured by the magnetic field in a region where the energy of randomizing thermal fluctuations is lower than the magnetic energy. The thermal energy of the particle at room temperature ( $T = 300\text{ K}$ ) is given by

$$E_T = \frac{3}{2}k_B \cdot T \approx 6 \cdot 10^{-21}\text{ J} \quad (1)$$

where  $k_B$  is the Boltzmann constant and  $T$  is temperature.

The magnetic energy can be expressed as the scalar product of the particle magnetic moment  $\mathbf{m}_p$  and the applied magnetic field  $\mathbf{H}$ <sup>39</sup>:

$$E_m = \frac{1}{2}\mu_0\mathbf{m}_p \cdot \mathbf{H} = \frac{1}{2}\mu_0(m_{p_x}H_x + m_{p_y}H_y + m_{p_z}H_z), \quad (2)$$

where  $\mu_0$  is the magnetic permeability of vacuum. Here the magnetisation of the water is considered negligible. Knowing the magnetic field generated by permanent magnets, we can define the magnetic moment of the MNPs at all the coordinates by using the experimental magnetization curve (Fig. 1d) and converting the magnetic units by:

$$\mathbf{m}_p [\text{Am}^2] = \mathbf{M}_m \left[ \frac{\text{emu}}{\text{g}} \right] \rho_m \left[ \frac{\text{g}}{\text{cm}^3} \right] V_m [\text{cm}^3] \cdot 10^{-3} \quad (3)$$


where  $M_m$ ,  $\rho_m$ ,  $V_m$  are magnetization (from magnetization curve), density and volume of the particle magnetic core, respectively. The detailed map of the spatial distribution of the magnetic energy of MNPs in the experimental configuration of the MagD is obtained from FEM simulations. The magnetic energy,  $E_m$ , is calculated applying

Eq. (2) and is compared with the thermal energy from Eq. (1), defining the conditions and areas where  $E_m(H) > 6 \times 10^{-21}$  J. The simulations are performed for spherical nanoparticles with 8 nm diameter of the magnetite core. This value is taken assuming that the magnetic confinement and dynamics is dominated by the 7 and 9 nm large MNPs (see Fig. 1b and discussion below).

The results of these numerical simulations are shown in Fig. 6. It indicates the yz-plane distribution of the magnetic energy of nanoparticles via a colour map, where the colour scale starts from the thermal energy level. Namely, the white background corresponds to regions where the thermal energy dominates; the coloured regions to the area where magnetic confinement occurs. Figure 6b shows the magnetic energy distribution along the three axes of coordinates in comparison with the thermal energy indicated by a black horizontal line. The MNP magnetic energy exceeds the thermal energy for all the points along z-axis, for  $y < \pm 2.4$  mm and for  $x < \pm 3.5$  mm.

The magnetic energy, as shown in Fig. 6a, has a clepsydra-like profile: along the y-axis, the energy has a clear maximum centred in the gap between the magnets while along the z-axis presents two maxima at the magnet edges and a broad minimum in the middle. In the region around the magnets where the magnetic energy is higher than the thermal one, the randomizing effect of the Brownian motion is overcome by the stabilizing effect of the magnetic field. Once magnetic nanoparticles enter in that region they cannot be displaced by thermal fluctuation and remain confined there.

The clepsydra shape is additionally emphasized in Fig. 6c. The colour maps in Fig. 6c are split in magnetic energy isosurfaces, useful for a better understanding of the MNP magnetic dynamics. For a better comparison of the calculations and experimental data, in Fig. 6d we zoom further on the area occupied by the capillary, where the confining energy maps are compared with the distribution of nanoparticles from Fig. 3a, sketched by two fitting red curves and the black arrows indicate the direction of the magnetic forces locally acting on MNPs. The experimental clepsydra is confined within approximately a 200  $\mu\text{m}$  area at the capillary walls, and restricted to below 100  $\mu\text{m}$  in the centre. This looks somehow narrower than the clepsydra-like isosurface with the highest energy ( $1.9 \times 10^{-20}$  J) which still fits inside the capillary.



**Figure 6.** (a) The distribution of the magnetic energy in yz-plane for the experimental set-up (Fig. 2a,b). The color scale depicts the  $0.6\text{--}4.0 \times 10^{-20}$  J energy interval where  $E_m > E_T$ . The red arrows show the directions of magnetization in the magnets. (b) Magnetic energy distribution along the axes defined in (a) (x-axis orthogonal to the plane of the figure), while the black line represents the thermal energy. (c) Zooming of (a) with the isosurfaces of magnetic energy between the magnets. (d) The further zooming of the working area to compare the magnetic energy maps with the confinement of nanoparticles from Fig. 3a, sketched by two red dashed lines. The black arrows show the direction of the magnetic forces acting on nanoparticles.

The explanation of this apparent deviation can be given both qualitatively and quantitatively. The qualitative explanation is backed by the distribution of the magnetic forces shown in Fig. 6d. Inside this isosurface the magnetic forces push the nanoparticles towards the central vertical axis, while the round-like shape is provided by the rotation of the gradual magnetic forces when approaching the capillary wall. Quantitatively, the explanation of the shape of the CSC is in agreement with thermodynamical models on confinement of Brownian particles by external forces<sup>40,41</sup>. It has been shown that the strict confinement is realised in areas where the deep potential (magnetic energy in our case) is about 4 times higher than the thermal energy. This is in good agreement with experimental and calculated data presented in Fig. 3 and Fig. 6d, where the confinement is realised for  $E_m$  ( $H$ )  $\geq 1.9 \times 10^{-20}$  J, which is about 3.2 times over the thermal energy.

It is worth highlighting here, that the MNP solution is physically constrained by the capillary, which is where the MNPs can be confined in a stable configuration not coalescing into the energy maxima located at the edges of magnets (Fig. 3c).

We now expand our calculations for MNPs from same magnetic material but different diameters of the magnetic core. The energy  $E_m$  of nanoparticle is directly proportional to its magnetic moment  $m_p$  and the applied field  $H$ , where  $m_p$  is proportional to the particle magnetization, its density and its volume (Eqs. (2) and (3)). Thus, the ratio of magnetic energy for two MNPs having magnetic diameters  $d_{p1}$  and  $d_{p2}$  is:


$$\frac{E_{m2}}{E_{m1}} = \frac{d_{p2}^3}{d_{p1}^3} \quad (4)$$

This gives a linear dependence in logarithmic coordinates shown in Fig. 7a. It physically means that, using MNPs with larger magnetic diameter, the  $E_m$  scales as the third power leading to an enlargement of the area where the MNP are magnetically trapped. Yet, as superparamagnetic-ferromagnetic transition happens at around 20 nm, inter-particle aggregation effects must be considered for diameters exceeding that value.

Figure 7b shows the maximum magnetic moment  $m_{p\_max}$  achievable in the superparamagnetic regime for employed iron oxide nanoparticles. Assuming a magnetic field sufficient to saturate the particle magnetization 60 emu/g and a density of 5.2 g/cm<sup>3</sup>, the magnetic moment is  $m_{p\_max}(\text{Am}^2) \approx 1.6 \times 10^{-22} \cdot d_p(\text{nm})^3$  (Fig. 7b). For example, for 8 nm MNPs the magnetic moment can achieve  $m_{p\_max}(\text{Am}^2) = 0.84 \times 10^{-19} \text{Am}^2$ . For the largest superparamagnetic 20 nm nanoparticle we can achieve the maximum magnetic moment of about  $13 \times 10^{-19} \text{Am}^2$ .

Summarizing, we showed that, via a proper selection of permanent magnets (considering their shape, orientation, distancing and magnetic intensity), it is possible to achieve high and sharply confined magnetic fields, able to trap and control small SP-MNP on sub- $\mu\text{m}$  scales. We accurately define the conditions at which the magnetic energy exceeds the destabilizing thermal kinetic energy of the nanoparticles, as function of external magnetic field, particle magnetisation and particle diameter.

While our experimental data cannot rule out the formation of aggregates or chains of MNPs in the MagD device<sup>42,43</sup>, our theoretical analysis demonstrates that their existence is not essential for magnetic confinement and control. Indeed, our experimental data are fully explained by a single-particle model where the MNPs act independently in the magnetic field. Moreover, straightforward calculations demonstrate that the magnetic fields generated by the presented magnetic configuration (Figs. 2 and 6) can trap superparamagnetic nanoparticles as small as 7–8 nm, in contrast with the previously proposed 50 nm lower bound for the control of magnetic nanoparticles by external magnetic fields<sup>43</sup>. Our results also indicate that the confinement of extremely low concentrations of nanoparticles, orders of magnitude below the visualization level, is possible. It would require a reasonably high magnetization of the MNPs, like the one shown in Fig. 1d, which is nevertheless reasonable for state-of-art magnetite iron oxide nanoparticles. Finally, there is an excellent agreement between the experimentally detected and the calculated clepsydra-like shapes, the latter resulting from a joint magnetic and physical (by the capillary) confinement of the nanoparticles.



**Figure 7.** (a) Ratio of magnetic energy  $E_m$  for two similar MNPs having magnetic diameters  $d_{p1}$  and  $d_{p2}$  in the same magnetic field. (b) Maximal magnetic moment of the particle  $m_{p\_max}$  versus its magnetic diameter  $d_p$ .

From Eq. (2) we can also say that for whatever small diameter of a magnetic nanoparticle, there exist a magnetic field  $H$  able to induce a magnetic energy exceeding the thermal energy. Our experiments show that standard commercial permanent magnets are well suited to control sub-10 nm nanoparticle, while much smaller nanoparticles (based on the same material) may require fields hardly achievable in laboratory conditions.

Considering the CSC stability during motion (Fig. 5), a comprehensive explanation would require an accurate knowledge of the hydrodynamic diameter of the MNPs. This parameter is typically measured by Dynamic light scattering (DLS), which however leads to considerable overestimations of the diameter of the nanoparticles due to the effects of multiple scattering and the assumption of spherical particles<sup>44</sup>. Indeed, the DLS measurements performed on these nanoparticles, characterized by a total diameter of 10 and a magnetic core with a diameter of 7–8 nm (see above), gave hydrodynamic diameters of  $65 \pm 29$  nm. Both the size overestimation and the substantial error do not allow, in our opinion, to correctly interpret the experimental data in Fig. 5. A more accurate definition of the hydrodynamic diameter is possible from direct measurements of the diffusivity of MNPs currently under investigation. We anticipate nevertheless that the stability of the CSC during motion should be more instable at low MNPs concentrations, in pure single particle regimes, while possible aggregates with large magnetic moments would solidly follow the motion of magnets.

Finally, we would like to underline that the possibility to individually control ultra-small nanoparticles is crucial for bio-applications, enabling the one-to-one capture of various proteins or viruses, typically in the same range of sizes. Such capability is critical in diagnostics, where the magnetic labelling can allow not only for the detection of selected bio-agents by magnetic sensors but can also permit their statistically accurate quantification.

## Conclusions

An experimental set-up—consisting of properly shaped permanent magnets and a capillary system—was employed to confine small superparamagnetic nanoparticles in sub-mm spatial shapes. We also demonstrate that it is possible to move the whole batch of nanoparticles with speeds depending on the distance between magnets. We give a mathematically accurate description of the confinement of nanoparticles by magnetic field, and define the conditions for which the magnetic energy overcomes the Brownian motion. Our experiments and calculations indicate that magnetic systems based on standard commercial permanent magnets can be successfully used for the trapping and manipulation of SP-MNP for various applications.

## Data availability

Correspondence and requests for material should be addressed to AS, TS and VAD.

Received: 23 December 2022; Accepted: 25 March 2023

Published online: 31 March 2023

## References

- Pankhurst, Q. A., Connolly, J., Jones, S. K. & Dobson, J. Applications of magnetic nanoparticles in biomedicine. *J. Phys. D Appl. Phys.* **36**, R167–R181 (2003).
- Wu, K., Su, D., Liu, J., Saha, R. & Wang, J.-P. Magnetic nanoparticles in nanomedicine: A review of recent advances. *Nanotechnology* **30**, 502003 (2019).
- Das, P., Colombo, M. & Prosperi, D. Recent advances in magnetic fluid hyperthermia for cancer therapy. *Colloids. Surf. B Biointerfaces* **174**, 42–55 (2019).
- Price, P. M., Mahmoud, W. E., Al-Ghamdi, A. A. & Bronstein, L. M. Magnetic Drug delivery: Where the field is going. *Front. Chem.* **6**, 619 (2018).
- Lima-Tenorio, M. K., Gomez Pineda, E. A., Ahmad, N. M., Fessi, H. & Elaissari, A. Magnetic nanoparticles: In vivo cancer diagnosis and therapy. *Int. J. Pharm* **493**, 313–327 (2015).
- Sharma, B. & Pervushin, K. Magnetic nanoparticles as in vivo tracers for Alzheimer's disease. *Magnetochemistry* **6**, 13 (2020).
- Kiplagat, A., Martin, D. R., Onani, M. O. & Meyer, M. Aptamer-conjugated magnetic nanoparticles for the efficient capture of cancer biomarker proteins. *J. Magn. Mater.* **497**, 166063 (2020).
- Tavallaie, R. *et al.* Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood. *Nat. Nanotech.* **13**, 1066–1017 (2018).
- Chang, C.-W., Yang, S.-Y., Yang, C.-C., Chang, C.-W. & Wu, Y.-R. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson's disease. *Front. Neurol.* **10**, 1388 (2020).
- Chansoria, P., Liu, H., Christiansen, M. G., Shürle-Finke, S. & Zenobi-Wong, M. Untethered: Using remote magnetic fields for regenerative medicine. *Trends Biotech.* <https://doi.org/10.1016/j.tibtech.2022.09.003> (2022).
- Goranov, V. *et al.* 3D patterning of cells in magnetic scaffolds for tissue engineering. *Sci. Rep.* **10**, 2289 (2020).
- Du, V. *et al.* A 3D magnetic tissue stretcher for remote mechanical control of embryonic stem cell differentiation. *Nat. Commun.* **8**, 400 (2017).
- Del-Sol-Fernandez, S. *et al.* Magnetogenetics: Remote activation of cellular functions triggered by magnetic switches. *Nanoscale* **14**, 2091–2118 (2022).
- Wheeler, M. A. *et al.* Genetically targeted magnetic control of the nervous system. *Nat. Neurosci.* **19**, 756–761 (2016).
- Iranmanesh, M. & Hulliger, J. Magnetic separation: Its application in mining, waste purification, medicine, biochemistry and chemistry. *Chem. Soc. Rev.* **46**, 5925–5934 (2017).
- Blümler, P. Magnetic guiding with permanent magnets: Concept, realization and applications to nanoparticles and cells. *Cells* **10**, 2708 (2021).
- Lewin, M. *et al.* Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. *Nat. Biotechnol.* **18**, 410–414 (2000).
- Nam, J.-M., Thaxton, C. S. & Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. *Science* **301**, 1884–1186 (2003).
- Leong, S. S., Yeap, S. P. & Lim, J. Working principle and application of magnetic separation for biomedical diagnostic at high- and low-field gradients. *Interface Focus* **6**, 20160048 (2016).
- van Rennen, A., de Jong, A. M., den Toonder, J. M. J. & Prins, M. W. J. Integrated lab-on-chip biosensing system based on magnetic particle actuation—A comprehensive review. *Lab. Chip* **14**, 1966–1986 (2014).
- Squires, T. M. & Quake, S. R. Microfluidics: Fluid physics at the nanoliter scale. *Rev. Mod. Phys.* **77**, 977–1026 (2005).



22. Nishijima, S. Application of superconductivity for magnetic force control in medical and industrial fields. *Physica C* **468**, 1115–1119 (2008).
23. Takeda, S.-I., Mishima, F., Fujimoto, S., Izumi, Y. & Nishijima, S. Development of magnetically targeted drug delivery system using superconducting magnet. *J. Magn. Magn. Mater.* **311**, 367–371 (2007).
24. Kelland, D. R. High gradient magnetic separation applied to mineral beneficiation. *IEEE Trans. Magn.* **9**, 307–310 (1973).
25. Ge, W., Encinas, A., Arājuo, E. & Song, S. Magnetic matrices used in high gradient magnetic separation (HGMS): A review. *Res. Phys.* **7**, 4278–4286 (2017).
26. Cao, Q. *et al.* Targeting behavior of magnetic particles under gradient magnetic fields produced by two types of permanent magnets. *IEEE Trans. Appl. Superconduct.* **26**, 4401305 (2016).
27. Han, X. *et al.* Numerical and Experimental investigations on the manipulation of magnetic particles in a microsystem using a hybrid magnet system. *IEEE Trans. Appl. Superconduct.* **26**, 4401904 (2016).
28. Cao, Q., Liu, M., Wang, Z., Han, X. & Li, L. Dynamic motion analysis of magnetic particles in microfluidic systems under an external gradient magnetic field. *Microfluid. Nanofluid.* **21**, 24 (2017).
29. Johansson, L. E. *et al.* A magnetic microchip for controlled transport of attomole levels of proteins. *Lab. Chip* **10**, 654–661 (2010).
30. Lee, C. S., Lee, H. & Westervelt, R. M. Microelectromagnets for the control of magnetic nanoparticles. *Appl. Phys. Lett.* **79**, 3308–3310 (2001).
31. van Pelt, S., den Frijns, A. & Toonder, J. Microfluidic magnetic bead conveyor belt. *Lab. Chip* **17**, 3826–3840 (2017).
32. Helseth, L. E., Fischer, T. M. & Johansen, T. H. Domain wall tip for manipulation of magnetic particles. *Phys. Rev. Lett.* **91**, 208302 (2003).
33. Donolato, M. *et al.* On-chip manipulation of protein-coated magnetic beads via domain-wall conduits. *Adv. Mater.* **22**, 2706–2710 (2010).
34. Massart, R. Preparation of aqueous magnetic liquids in alkaline and acidic media. *IEEE Trans. Magn.* **17**, 1247–1248 (1981).
35. Karaagac, O. & Kockar, H. A simple way to obtain high saturation magnetization for superparamagnetic iron oxide nanoparticles synthesized in air atmosphere: optimization by experimental design. *J. Magn. Magn. Mat.* **409**, 116–123 (2016).
36. Bean, C. P. & Livingston, J. D. Superparamagnetism. *J. Appl. Phys.* **30**, S120–S129 (1959).
37. Galvão, W. S., Neto, D. M. N. A., Freire, R. M. & Fechine, P. B. A. Super-paramagnetic nanoparticles with spinel structure: A review of synthesis and biomedical applications. *Solid State Phenom.* **241**, 139–176 (2013).
38. Kolen'ko, Y.V., Bañobre-Lopez, M., Rodriguez-Abreu, C., Carbó-Argibay, E., Sailsman, A., Piñero-Redondo, Y., Fátima Cerqueira, M., Petrovykh, D.Y., Kovnir, K., Lebedev, O.I., & Rivas, J. Large-scale synthesis of colloidal Fe<sub>3</sub>O<sub>4</sub> nanoparticles exhibiting high heating efficiency in magnetic hyperthermia. *J. Phys. Chem. C* **118**, 8691–8701 (2014).
39. Friedman, G. & Yellen, B. Magnetic separation, manipulation and assembly of solid phase in fluids. *Curr. Opin. Colloid Interface Sci.* **10**, 158–166 (2005).
40. Ferrando, R., Spadacini, R. & Tommei, G. E. Kramers problem in periodic potentials: Jump rate and jump lengths. *Phys. Rev. E* **48**, 2437–2451 (1993).
41. Dechant, A., Kindermann, F., Widera, A. & Lutz, E. Continuous-time random walk for a particle in a periodic potential. *Phys. Rev. Lett.* **123**, 070602 (2019).
42. Zubarev, A. Y. & Iskakova, L. Y. Condensation phase transition in ferrofluids. *Physica A* **335**, 325–338 (2004).
43. Mandel, K. & Hutter, F. The magnetic nanoparticle separation problem. *Nano Today* **7**, 485–487 (2012).
44. Modena, M. M., Rühle, B., Burg, T. P. & Wuttke, S. Nanoparticle characterization: What to measure?. *Adv. Mater.* **31**, 1901556 (2019).

## Acknowledgements

The authors thank Federico Bona for technical assistance and Alberto Riminucci for illuminating discussions.

## Author contributions

A.S. performed the experiments and analysed the experimental results. T.S. performed the FEM simulations. M.M. fabricated the MagD device. J.R. and Y.P. fabricated and characterized the SP-MNPs. P.G. performed the experiments. M.F. and V.A.D. were in charge of project administration and funding acquisition. A.S., T.S. and V.A.D. conceptualized the experiments and wrote the manuscript. A.S. and T.S. contributed equally to the work. All authors read and approved the final manuscript.

## Funding

This research has been funded from the European Union's Horizon 2020 research and innovation programme under the projects MADIA—MAGnetic Diagnostic Assay for neurodegenerative disease—grant agreement no. 732678 and BOW—Biogenic Organotropic Wetsuits—grant agreement no. 952183.

## Competing interests

The authors declare no competing interests.

## Additional information

**Correspondence** and requests for materials should be addressed to A.S., T.S. or V.A.D.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023